Position in GH
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$113,631,671
+$41,615,586 QoQ
Shares Held
757,393
-2.9% QoQ
Ownership
0.564%
of shares outstanding
% of Portfolio
8.60%
of 13F equity value
Holder Rank
#43
of 594 holders
Holding Since
Dec 2023
11 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in GH Over Time
Shares Held
Position Value (USD)
Derivatives in GH
reported options exposure · as of Sep 30, 2024CallValue
$1,777,850
CallShares
77,500
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Diagnostics & Research
Healthcare · as of Jun 30, 2026CADIAN CAPITAL MANAGEMENT, LP holds $339,572,252 across 4 Diagnostics & Research names. GH ranks #2 (33.5% of the industry book) .
All Filings in GH
Export CSV
12 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $113,631,671 | 757,393 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $72,016,085 | 779,648 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $94,237,223 | 922,628 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $133,781,613 | 2,141,191 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $165,446,452 | 3,179,217 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $195,750,706 | 4,595,087 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $159,518,810 | 5,221,565 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $158,985,073 | 6,930,474 | Shares | Sole | 2024-11-14 | |
| 2024-09-30 | $1,777,850 | 77,500 | Call | Sole | 2024-11-14 | |
| 2024-06-30 | $90,446,615 | 3,131,808 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $119,505,030 | 5,792,779 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 | $19,205,500 | 710,000 | Shares | Sole | 2024-02-14 | |
| No filing history on record for this holder in this stock. | ||||||